Historial de ingresos, beneficios y flujo de caja según los estados financieros oficiales.
ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.
Ver gráficos interactivos y estados completos → Modelo de valoración (DCF) →
| Cuenta de resultados | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 | 2014-12-31 | 2013-12-31 | 2012-12-31 | 2011-12-31 | 2010-12-31 | 2009-12-31 | 2008-12-31 | 2007-12-31 | 2006-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ingresos totales | $8.3B | $8.3B | $8.3B | $8.1B | $7.7B | $5.5B | $2.8B | $2.8B | $2.6B | $1.8B | $1.7B | $1.6B | $1.5B | $1.3B | $1.1B | $946M | $900M | $888M | $865M | $631M | $456M |
| Beneficio bruto | $1.9B | $2.2B | $2.4B | $2.4B | $2.2B | $1.5B | $808M | $832M | $769M | $727M | $705M | $666M | $600M | $491M | $397M | $334M | $359M | $380M | $376M | $276M | $199M |
| % de margen bruto | 23.0% | 26.4% | 29.4% | 29.6% | 28.6% | 27.5% | 28.9% | 29.6% | 29.6% | 41.3% | 42.3% | 42.3% | 39.9% | 36.7% | 35.6% | 35.3% | 39.9% | 42.8% | 43.5% | 43.8% | 43.8% |
| Ingresos operativos (EBIT) | $857M | $1.0B | $1.1B | $956M | $795M | $379M | $392M | $433M | $373M | $338M | $312M | $282M | $202M | $121M | $72M | $39M | $92M | $107M | $100M | $69M | $48M |
| % de margen operativo | 10.3% | 12.3% | 13.3% | 11.8% | 10.3% | 6.9% | 14.0% | 15.4% | 14.4% | 19.2% | 18.7% | 17.9% | 13.5% | 9.1% | 6.5% | 4.2% | 10.2% | 12.1% | 11.5% | 11.0% | 10.5% |
| Ingresos netos | $70M | $229M | $791M | $612M | $505M | $153M | $328M | $374M | $323M | $281M | $262M | $240M | $172M | $103M | $55M | $23M | $87M | $94M | $78M | $56M | $38M |
| % de margen neto | 0.8% | 2.8% | 9.6% | 7.5% | 6.5% | 2.8% | 11.7% | 13.3% | 12.4% | 16.0% | 15.7% | 15.2% | 11.5% | 7.7% | 5.0% | 2.4% | 9.7% | 10.6% | 9.0% | 8.9% | 8.4% |
| EBITDA | — | $824M | $1.6B | $1.5B | $1.4B | $739M | $489M | $532M | $452M | $402M | $379M | $339M | $264M | $169M | $111M | $69M | $128M | $141M | $130M | $88M | $63M |
| Beneficio por acción (EPS) | $0.89 | $2.90 | $9.53 | $7.40 | $6.13 | $2.25 | $6.15 | $6.88 | $5.90 | $5.13 | $4.65 | $3.97 | $2.73 | $1.65 | $0.91 | $0.37 | $1.44 | $1.57 | $1.30 | $1.88 | $1.33 |
| Acciones en circulación (M) | — | 79M | 83M | 83M | 82M | 68M | 53M | 54M | 55M | 55M | 56M | 60M | 63M | 62M | 61M | 61M | 61M | 60M | 60M | 30M | 29M |
Fuente: informes públicos de la empresa (SEC). Verifique en SEC EDGAR antes de confiar en cualquier cifra.
Balances, flujos de caja, datos trimestrales y ratios completos en el visor interactivo de ICLR. /companies/us/ICLR
La información de este sitio es solo educativa e informativa; no constituye asesoramiento de inversión. No se publican precios objetivo ni recomendaciones.
About TickerBase · Data methodology & sources · Privacy · Terms